查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041838

2034年全球血液傳染病檢查市場預測－按產品類型、病原體類型、檢測方法、技術、最終用戶和地區分類的分析

Bloodstream Infection Testing Market Forecasts to 2034 - Global Analysis By Product Type, By Pathogen Type, Testing, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球血液傳染病檢查市場規模將達到 79 億美元，並在預測期內以 9.3% 的複合年成長率成長，到 2034 年將達到 161 億美元。

血液傳染病檢查是指旨在識別血液中微生物病原體的診斷程序。此檢測利用多種技術，包括血液培養和分子生物學方法，來檢測引起性行為感染的細菌、病毒或真菌。它在早期發現、指導適當的治療決策和防止感染疾病傳播方面發揮著至關重要的作用，從而對全球患者照護和公共衛生產生重大影響。

根據全球最大的醫學圖書館—美國國家醫學圖書館（NLM）的數據顯示，血流感染疾病（BSI）是全球主要的疾病和死亡原因之一。血流感染的發生率呈上升趨勢，每10萬人發病率在122至220例之間。

全球血液感染疾病病例增加

全球血流感染疾病（BSI）病例的驚人成長是推動傳染病檢查市場發展的強大動力。這一激增歸因於多種因素，例如抗生素抗藥性的上升、侵入性醫療操作以及人口老化導致老年人更容易感染疾病。對快速準確識別致病菌的需求日益成長，推動了快速分子檢測和自動化血液培養系統等先進診斷技術的發展。此外，人們對醫療相關感染（HAI）的認知不斷提高，促使醫院和診所增加對完善的BSI檢測方案的投資，進一步促進了市場擴張。

先進診斷技術高成本

雖然先進的診斷技術能夠提供更快、更準確的血液傳染病檢查，但其高昂的成本限制了其市場應用。這些先進的檢測通常需要昂貴的設備、專業的技師和複雜的流程，增加了醫療機構和病患的成本。這可能會限制其在資源匱乏環境中的應用，阻礙其廣泛普及，並可能削弱其為患者照護帶來的潛在益處。

醫護人員的意識

在血流傳染病檢查市場，意識提升蘊藏著巨大的機會。目前，許多醫護人員對最新的檢測方法以及早期發現血流感染的迫切性缺乏足夠的了解。透過對醫生、護士和其他醫護人員進行培訓，讓他們了解透過先進檢測快速識別和治療血流感染的益處，市場可以釋放巨大的成長潛力。這將有助於有效利用這一盈利的機遇，並推動市場擴張。

資料安全問題

由於血液傳染病檢查高度依賴數位資料，因此極易受到網路攻擊。駭客可能竊取敏感的患者資訊或篡改檢測結果，從而影響診斷並損害患者利益。這引發了人們對資料隱私、檢測準確性以及可能限制市場擴張的潛在法律問題的擔憂。

新冠疫情的影響：

新冠疫情對血液傳染病檢查產生了重大影響。醫療機構不得不優先將資源分配給新冠病毒檢測，導致常規血液感染疾病檢測的關注度降低。此外，感染控制措施、患者數量的增加以及醫療實踐的改變也加劇了檢查室能力壓力。疫情期間血液傳染病檢查的延遲和減少可能影響了及時診斷和治療，進而對患者預後產生負面影響，並需要對檢測策略和醫療服務系統進行調整。

在預測期內，設備細分市場預計將佔據最大的市場佔有率。

隨著血流感染疾病率的上升，儀器設備領域預計將佔據最大的市場佔有率。自動化血液培養系統、分子診斷平台和質譜儀在病原體的快速鑑定中發揮著至關重要的作用。此外，儀器技術的不斷進步，例如靈敏度和特異性的提高，也提升了這些設備的重要性，並成為血流傳染病檢查市場佔有率成長的主要促進因素。

在預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。

由於預防醫學意識的提高和診斷服務需求的成長，診斷檢查室領域預計將迎來顯著成長。診斷技術的進步使得檢測方法更加精準高效，吸引了更多患者。此外，慢性病盛行率的上升也使得定期監測變得特別必要，進而增加了對診斷中心的需求。新冠肺炎疫情也凸顯了便利高效的診斷設施的重要性，加速了全球診斷中心的擴張。

市佔率最大的地區：

北美憑藉其先進的醫療基礎設施和在研發領域的巨額投入，在血液傳染病檢查市場中保持著主導地位。此外，主要市場參與者的存在、行業與研究機構之間的合作以及健全的法規結構也促進了市場成長。同時，該地區積極採用創新診斷技術以及對感染控制重要性的日益重視，進一步鞏固了北美作為最大市場佔有率持有者的地位。

複合年成長率最高的地區：

亞太地區預計將迎來顯著成長，這主要得益於快速的都市化、不斷成長的醫療保健支出以及先進醫療技術的普及。此外，人口成長、健康意識的提高以及政府支持醫療基礎建設的各項措施也推動了這一成長趨勢。隨著中產階級的快速壯大和醫療保健體系的不斷完善，亞太地區為包括醫療保健和診斷在內的各行各業提供了巨大的市場拓展機會。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球血液傳染病檢查市場：依產品類型分類

  • 裝置
    • 自動化血液培養系統
    • 聚合酵素鏈鎖反應（PCR）裝置
  • 消耗品
    • 血液培養瓶
    • 試劑
  • 軟體
    • 數據分析軟體
    • 報告建立和解讀軟體

第6章 全球血液傳染病檢查市場：依病原體類型分類

  • 細菌性血流感染疾病
  • 黴菌血流感染疾病
  • 病毒性血流感染疾病

第7章 全球血液傳染病檢查市場：依檢測類型分類

  • 血液培養試驗
    • 常規血液培養
    • 自動血液培養
  • 分子診斷
    • 聚合酵素鏈鎖反應（PCR）
    • 核酸擴增法（NAAT）
  • 微生物檢測
  • 免疫學檢測

第8章 全球血液傳染病檢查市場：依技術分類

  • 傳統文化技術
  • 質譜分析
  • 微陣列技術
  • 次世代定序（NGS）
  • 其他技術

第9章：全球血液傳染病檢查市場：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 學術研究機構
  • 即時檢測
  • 其他最終用戶

第10章 全球血液傳染病檢查市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Abbott Laboratories
  • Accelerate Diagnostics
  • Becton, Dickinson and Company（BD）
  • Biocartis
  • BioMerieux
  • Bio-Rad Laboratories
  • Bruker Corporation
  • Cepheid
  • Danaher Corporation
  • DiaSorin
  • GenMark Diagnostics
  • Grifols
  • Hologic, Inc.
  • Luminex Corporation
  • Molzym
  • OpGen
  • Qiagen
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
Product Code: SMRC24904

According to Stratistics MRC, the Global Bloodstream Infection Testing Market is accounted for $7.9 billion in 2026 and is expected to reach $16.1 billion by 2034 growing at a CAGR of 9.3% during the forecast period. Bloodstream infection testing involves diagnostic procedures aimed at identifying microbial pathogens in the bloodstream. This testing utilizes various techniques, including blood cultures and molecular methods, to detect bacteria, viruses, or fungi causing systemic infections. It plays a crucial role in early identification, guiding appropriate treatment decisions and preventing the spread of infections, significantly impacting patient care and public health on a worldwide scale.

According to the U.S. National Library of Medicine, world's largest medical library, Bloodstream Infections (BSIs) are a leading global cause of disease and mortality. The incidence of BSIs has grown over time and the rates ranges from 122 to 220 cases per 100,000 people.

Market Dynamics:

Driver:

Rising cases of bloodstream infections worldwide

The alarming rise in bloodstream infections (BSIs) across the globe is acting as a potent fuel for the bloodstream infection testing market. This surge is attributed to factors like increasing antibiotic resistance, invasive medical procedures and an aging population that is more susceptible to infections. This growing demand for rapid and precise identification of causative pathogens is driving the market for advanced diagnostic technologies like rapid molecular tests and automated blood culture systems. Additionally, heightened awareness about healthcare-associated infections (HAIs) is prompting hospitals and clinics to invest in robust BSI testing protocols, further propelling the market's expansion.

Restraint:

High costs associated with advanced diagnostic technologies

Advanced diagnostic technologies offer faster and more accurate bloodstream infection testing, their high price tag acts as a major market restraint. These sophisticated tests often require expensive equipment, specialized technicians, and complex workflows, driving up costs for both healthcare providers and patients. This can limit their accessibility in resource-constrained settings and discourage their widespread adoption, hindering the potential benefits they bring to patient care.

Opportunity:

Awareness among healthcare professionals

A crucial opportunity lies in raising awareness among healthcare professionals within the bloodstream infection testing market. Currently, many practitioners lack sufficient knowledge about the latest testing methods or the urgency of early BSI detection. By educating doctors, nurses and other medical staff on the rapid identification and treatment benefits of advanced testing, the market can unlock significant growth potential, which can effectively tap into this lucrative opportunity and drive market expansion.

Threat:

Data security concerns

Bloodstream infection testing relies heavily on digital data, making it vulnerable to cyberattacks. Hackers could steal sensitive patient information or manipulate test results, impacting diagnoses and potentially harming patients. This raises concerns about data privacy, trust in test accuracy and potential legal repercussions that limit market expansion.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted bloodstream infection testing. Medical facilities faced challenges in prioritizing resources for COVID-19 testing, potentially reducing attention to routine testing for bloodstream infections. Additionally, infection control measures, increased patient loads, and altered healthcare practices strained laboratory capacities. Delayed or reduced testing for bloodstream infections during the pandemic might have affected timely diagnosis and treatment, potentially impacting patient outcomes and necessitating adaptations in testing strategies and healthcare delivery.

The instrument segment is expected to be the largest during the forecast period

The instrument segment is poised to secure the largest market share in the market due to the increasing prevalence of bloodstream infections. Automated blood culture systems, molecular diagnostic platforms, and mass spectrometers play pivotal roles in identifying pathogens swiftly. Additionally, continuous advancements in instrument technologies, such as improved sensitivity and specificity, bolster their prominence, making them the leading contributor to the market share for bloodstream infection testing.

The diagnostics laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostics laboratories segment is poised for significant growth due to increased awareness of preventive healthcare and amplified demand for diagnostic services. Technological advancements in diagnostics have led to more accurate and efficient testing methods, attracting more patients. Additionally, the rising prevalence of chronic diseases necessitates regular monitoring, boosting the need for diagnostic center services. Moreover, the COVID-19 pandemic emphasized the importance of accessible and efficient diagnostic facilities, fostering the expansion of diagnostics centers globally.

Region with largest share:

North America's dominance in the bloodstream infection testing market is owing to its advanced healthcare infrastructure and significant investments in research and development. Moreover, the presence of key market players, collaborations between industry and research institutions, and robust regulatory frameworks contribute to market growth. Additionally, the region's proactive adoption of innovative diagnostic technologies and heightened awareness about the importance of infection control further solidify North America's position in securing the largest market share.

Region with highest CAGR:

The Asia-Pacific region is positioned for significant growth due to rapid urbanization, increasing healthcare spending and expanding access to advanced medical technologies. Additionally, a growing population, rising awareness about health issues, and government initiatives supporting healthcare infrastructure development contribute to this trajectory. With a burgeoning middle class and evolving healthcare systems, the Asia-Pacific region presents immense opportunities for market expansion across various industries, including healthcare and diagnostics.

Key players in the market

Some of the key players in Bloodstream Infection Testing Market include Abbott Laboratories, Accelerate Diagnostics, Becton, Dickinson and Company (BD), Biocartis, BioMerieux, Bio-Rad Laboratories, Bruker Corporation, Cepheid, Danaher Corporation, DiaSorin, GenMark Diagnostics, Grifols, Hologic, Inc., Luminex Corporation, Molzym, OpGen, Qiagen, Roche Diagnostics, Sysmex Corporation and Thermo Fisher Scientific.

Key Developments:

In October 2023, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company and APIS Assay Technologies Ltd. ('APIS'), a private UK based company specializing in molecular diagnostics, today announced the expansion of their partnership1 to include the commercialization of the APIS ESR1 Mutations Kit through Biocartis' worldwide commercial network.

In October 2023, Oxford Nanopore Technologies plc ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMerieux SA, a world leader in the field of in vitro diagnostics ("IVD") announced that bioMerieux is making an immediate £70M investment in Oxford Nanopore.

Product Types Covered:

  • Instruments
  • Consumables
  • Services

Pathogen Types Covered:

  • Bacterial Bloodstream Infections
  • Fungal Bloodstream Infections
  • Viral Bloodstream Infections

Testings Covered:

  • Blood Culture Test
  • Molecular Diagnostics
  • Microbiological Testing
  • Immunological Testing

Technologies Covered:

  • Conventional Culture Technology
  • Mass Spectrometry
  • Microarray Technology
  • Next-Generation Sequencing (NGS)
  • Other Technologies

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Point-of-Care Testing
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bloodstream Infection Testing Market, By Product Type

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Automated Blood Culture Systems
    • 5.2.2 Polymerase Chain Reaction (PCR) Instruments
  • 5.3 Consumables
    • 5.3.1 Blood Culture Bottles
    • 5.3.2 Reagents
  • 5.4 Software
    • 5.4.1 Data Analysis Software
    • 5.4.2 Reporting and Interpretation Software

6 Global Bloodstream Infection Testing Market, By Pathogen Type

  • 6.1 Introduction
  • 6.2 Bacterial Bloodstream Infections
  • 6.3 Fungal Bloodstream Infections
  • 6.4 Viral Bloodstream Infections

7 Global Bloodstream Infection Testing Market, By Testing

  • 7.1 Introduction
  • 7.2 Blood Culture Test
    • 7.2.1 Conventional Blood Culture
    • 7.2.2 Automated Blood Culture
  • 7.3 Molecular Diagnostics
    • 7.3.1 Polymerase Chain Reaction (PCR)
    • 7.3.2 Nucleic Acid Amplification Techniques (NAAT)
  • 7.4 Microbiological Testing
  • 7.5 Immunological Testing

8 Global Bloodstream Infection Testing Market, By Technology

  • 8.1 Introduction
  • 8.2 Conventional Culture Technology
  • 8.3 Mass Spectrometry
  • 8.4 Microarray Technology
  • 8.5 Next-Generation Sequencing (NGS)
  • 8.6 Other Technologies

9 Global Bloodstream Infection Testing Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Diagnostic Laboratories
  • 9.4 Academic and Research Institutes
  • 9.5 Point-of-Care Testing
  • 9.6 Other End Users

10 Global Bloodstream Infection Testing Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Accelerate Diagnostics
  • 12.3 Becton, Dickinson and Company (BD)
  • 12.4 Biocartis
  • 12.5 BioMerieux
  • 12.6 Bio-Rad Laboratories
  • 12.7 Bruker Corporation
  • 12.8 Cepheid
  • 12.9 Danaher Corporation
  • 12.10 DiaSorin
  • 12.11 GenMark Diagnostics
  • 12.12 Grifols
  • 12.13 Hologic, Inc.
  • 12.14 Luminex Corporation
  • 12.15 Molzym
  • 12.16 OpGen
  • 12.17 Qiagen
  • 12.18 Roche Diagnostics
  • 12.19 Sysmex Corporation
  • 12.20 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Bloodstream Infection Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Bloodstream Infection Testing Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Bloodstream Infection Testing Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 4 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture Systems (2023-2034) ($MN)
  • Table 5 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) Instruments (2023-2034) ($MN)
  • Table 6 Global Bloodstream Infection Testing Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 7 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Bottles (2023-2034) ($MN)
  • Table 8 Global Bloodstream Infection Testing Market Outlook, By Reagents (2023-2034) ($MN)
  • Table 9 Global Bloodstream Infection Testing Market Outlook, By Software (2023-2034) ($MN)
  • Table 10 Global Bloodstream Infection Testing Market Outlook, By Data Analysis Software (2023-2034) ($MN)
  • Table 11 Global Bloodstream Infection Testing Market Outlook, By Reporting and Interpretation Software (2023-2034) ($MN)
  • Table 12 Global Bloodstream Infection Testing Market Outlook, By Pathogen Type (2023-2034) ($MN)
  • Table 13 Global Bloodstream Infection Testing Market Outlook, By Bacterial Bloodstream Infections (2023-2034) ($MN)
  • Table 14 Global Bloodstream Infection Testing Market Outlook, By Fungal Bloodstream Infections (2023-2034) ($MN)
  • Table 15 Global Bloodstream Infection Testing Market Outlook, By Viral Bloodstream Infections (2023-2034) ($MN)
  • Table 16 Global Bloodstream Infection Testing Market Outlook, By Testing (2023-2034) ($MN)
  • Table 17 Global Bloodstream Infection Testing Market Outlook, By Blood Culture Test (2023-2034) ($MN)
  • Table 18 Global Bloodstream Infection Testing Market Outlook, By Conventional Blood Culture (2023-2034) ($MN)
  • Table 19 Global Bloodstream Infection Testing Market Outlook, By Automated Blood Culture (2023-2034) ($MN)
  • Table 20 Global Bloodstream Infection Testing Market Outlook, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 21 Global Bloodstream Infection Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2023-2034) ($MN)
  • Table 22 Global Bloodstream Infection Testing Market Outlook, By Nucleic Acid Amplification Techniques (NAAT) (2023-2034) ($MN)
  • Table 23 Global Bloodstream Infection Testing Market Outlook, By Microbiological Testing (2023-2034) ($MN)
  • Table 24 Global Bloodstream Infection Testing Market Outlook, By Immunological Testing (2023-2034) ($MN)
  • Table 25 Global Bloodstream Infection Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 26 Global Bloodstream Infection Testing Market Outlook, By Conventional Culture Technology (2023-2034) ($MN)
  • Table 27 Global Bloodstream Infection Testing Market Outlook, By Mass Spectrometry (2023-2034) ($MN)
  • Table 28 Global Bloodstream Infection Testing Market Outlook, By Microarray Technology (2023-2034) ($MN)
  • Table 29 Global Bloodstream Infection Testing Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 30 Global Bloodstream Infection Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 31 Global Bloodstream Infection Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 32 Global Bloodstream Infection Testing Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 33 Global Bloodstream Infection Testing Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 34 Global Bloodstream Infection Testing Market Outlook, By Academic and Research Institutes (2023-2034) ($MN)
  • Table 35 Global Bloodstream Infection Testing Market Outlook, By Point-of-Care Testing (2023-2034) ($MN)
  • Table 36 Global Bloodstream Infection Testing Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.